243 related articles for article (PubMed ID: 24045880)
1. Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.
Varela FA; Der-Ghazarian T; Lee RJ; Charntikov S; Crawford CA; McDougall SA
J Psychopharmacol; 2014 Apr; 28(4):376-86. PubMed ID: 24045880
[TBL] [Abstract][Full Text] [Related]
2. Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats.
Der-Ghazarian T; Charntikov S; Varela FA; Crawford CA; McDougall SA
J Neural Transm (Vienna); 2010 May; 117(5):573-83. PubMed ID: 20372943
[TBL] [Abstract][Full Text] [Related]
3. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.
Tadokoro S; Okamura N; Sekine Y; Kanahara N; Hashimoto K; Iyo M
Schizophr Bull; 2012 Sep; 38(5):1012-20. PubMed ID: 21402722
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum.
Inoue A; Miki S; Seto M; Kikuchi T; Morita S; Ueda H; Misu Y; Nakata Y
Eur J Pharmacol; 1997 Feb; 321(1):105-11. PubMed ID: 9083792
[TBL] [Abstract][Full Text] [Related]
5. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
Han M; Huang XF; Deng C
Int J Neuropsychopharmacol; 2009 Aug; 12(7):941-52. PubMed ID: 19203411
[TBL] [Abstract][Full Text] [Related]
7. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
[TBL] [Abstract][Full Text] [Related]
8. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats.
Oshibuchi H; Inada K; Sugawara H; Ishigooka J
Eur J Pharmacol; 2009 Aug; 615(1-3):83-90. PubMed ID: 19477171
[TBL] [Abstract][Full Text] [Related]
10. Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary.
Inoue A; Seto M; Sugita S; Hide I; Hirose T; Koga N; Kikuchi T; Nakata Y
Brain Res Mol Brain Res; 1998 Apr; 55(2):285-92. PubMed ID: 9582438
[TBL] [Abstract][Full Text] [Related]
11. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol.
Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I
Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
Leite JV; Guimarães FS; Moreira FA
Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
[TBL] [Abstract][Full Text] [Related]
13. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.
Koener B; Goursaud S; Van De Stadt M; Calas AG; Jeanjean AP; Maloteaux JM; Hermans E
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):65-77. PubMed ID: 21061116
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole.
Bäckström P; Etelälahti TJ; Hyytiä P
Addict Biol; 2011 Jan; 16(1):55-63. PubMed ID: 21158016
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission.
Tanahashi S; Yamamura S; Nakagawa M; Motomura E; Okada M
Neuropharmacology; 2012 Feb; 62(2):765-74. PubMed ID: 21925189
[TBL] [Abstract][Full Text] [Related]
17. Brexpiprazole has a low risk of dopamine D
Amada N; Akazawa H; Ohgi Y; Maeda K; Sugino H; Kurahashi N; Kikuchi T; Futamura T
Neuropsychopharmacol Rep; 2019 Dec; 39(4):279-288. PubMed ID: 31487433
[TBL] [Abstract][Full Text] [Related]
18. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
[TBL] [Abstract][Full Text] [Related]
19. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
[TBL] [Abstract][Full Text] [Related]
20. New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling.
Brust TF; Hayes MP; Roman DL; Watts VJ
Biochem Pharmacol; 2015 Jan; 93(1):85-91. PubMed ID: 25449598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
